Keep a loose eye on ONCS (CEO was INO CEO before KIm) - had a little action in pre & saw it pop a while ago so might be worth keeping on watch - nice vol & bio hit man Adam F not trashing it & actually thinks news is OK & Maxim positive, says good TAVO results would translate into significant incentive for Merck to support combination. OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients - https://finance.yahoo.com/news/oncosec-presents-positive-phase-2-100000776.html
hey there - GMNX +41% on insider buying. BDRBF starting to move higher: $2.22 keep an eye on NPTN: $5.15
my turn >> GMNX - not coming up??? On another note - glad i didn't hold VERI - watching for entry around $30 or lower & hope i time this one better.
Watching Qure (sold too soon AGAIN - might be some play up & down ) - couple IPO's >> REDU (China education/English - $14.50-$15. range) - any momo play that speaks to me in the morning. Thanks @Neil Allen saw IMMY this morning but was caught up with QURE so will see what it's doing in the morning.
Playing QURE & hoping for $18 but... waiting on REDU Had $18 but took my eyes off the chart to log in /post here so hoping for it again!!
Next week's IPO's: Ablynx ABLX Nasdaq $20.95 7,159,905 10/23/2017 BP Midstream Partners LP BPMP NYSE $19.00 - $21.00 42,500,000 10/23/2017 CM Seven Star Acquisition CMSSU Nasdaq $10.00 15,000,000 10/23/2017 ForeScout Technologies FSCT Nasdaq $20.00 - $22.00 4,800,000 10/23/2017 Haymaker Acquisition HAYU Nasdaq $10.00 30,000,000 10/23/2017 Hexindai HX Nasdaq $9.00 - $11.00 5,808,081 10/23/2017 Merchants Bancorp MBIN Nasdaq $17.00 - $19.00 5,555,555 10/23/2017 National Vision Holdings EYE Nasdaq $18.00 - $20.00 15,800,000 10/23/2017 Nexa Resources NEXA NYSE $18.00 - $21.00 31,000,000 10/23/2017
^^ thanks - will explore over weekend for next week. REDU is actually quite nice - moving a bit slower than others
Have to head out in a bit so sold REDU but keeping a little of this one too but sell set just in case. You might want to check this one out along with QURE which is still heading up nice - over $19 now.
Bio hit man Adam F brought this one down https://stockaholics.net/threads/ocul-ocular-therapeutix.1705/page-2
News: BDRBF: $2.25 partners w/Airbus to sell BDRBF's Jets: Airbus expects to sell 'thousands' of CSeries jets -CEO REUTERS 11:30 AM ET 10/20/2017 By Allison Lampert MONTREAL, Oct 20 (Reuters) - Airbus Chief Executive Tom Enders said on Friday he believed Bombardier Inc's CSeries planes would capture half the market for smaller single-aisle aircraft with the sale of "thousands" of the 110-to-130 seat jets. "I see no reason why we should not be able to capture 50 percent of that market," Enders said in Montreal at a breakfast organized by the city's chamber of commerce. "I think we will sell thousands." Europe's largest aerospace group on Monday agreed to take a majority stake in the CSeries program for $1, a move expected to reduce costs while bolstering the plane's sales and giving Canada's Bombardier a possible way out of a damaging trade dispute with Boeing Co(BA) and U.S. regulators. The lightweight, carbon-composite jet, which costs $6 billion to develop, has won performance accolades but failed to secure a sale in 18 months.
OCUL Analyst Price Target - TipRanks $15.50 ▲ (174.82% Upside) Based on 3 analysts offering 12 month price targets for OCUL in the last 3 months. The average price target is $15.50 with a high estimate of $21.00 and a low estimate of $10.00. (2) Buy; (1) hold. OCUL----------------- shares -----increased holdings BlackRock Inc. 1,380,100 89,355 Top (10) Hedge funds holding OCUL: https://www.holdingschannel.com/hedge-funds/holding-ocul/ No insider selling since 9/15/15. Earnings and Revenue Update: For the quarter ended June 30, 2017, Ocular Therapeutix Inc reported earnings of $-18.7 million or $-0.64 per share compared with $-16.0 million or $-0.58 per share for the prior quarter and $-11.4 million or $-0.46 per share for the same quarter one year ago. Revenues were $0.4 million for the quarter ended June 30, 2017 compared with $0.5 million for the prior quarter and $0.4 million for the same quarter one year ago. Last twelve months' earnings were $-2.12 per share compared with $-1.80 per share a year ago. Last twelve months' revenues were $1.9 million compared with $1.8 million a year ago.
